Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific TGM4 TGP ENSG00000163810 Transglutaminase 4 3 44874608-44914990 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032072, CAB033571 Supported Tissue enriched Tissue enriched 463 prostate: 688.5 adrenal gland: 1.4 KLK3 APS, PSA ENSG00000142515 Kallikrein-related peptidase 3 19 50854915-50860764 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000070, HPA000764 Supported Tissue enriched Tissue enriched 369 prostate: 12913.7 seminal vesicle: 34.9 ADAM2 CT15, FTNB, PH-30b, PH30 ENSG00000104755 ADAM metallopeptidase domain 2 8 39743735-39838289 Enzymes, Predicted membrane proteins Evidence at protein level CAB022390, HPA024621, HPA026581 Supported Tissue enhanced Tissue enriched 288 testis: 41.7 breast: 0.1 INSL5 ENSG00000172410 Insulin-like 5 1 66797741-66801256 Predicted secreted proteins Evidence at protein level HPA030100, CAB033849 Supported Group enriched Group enriched 231 colon: 79.8;rectum: 143.8 cerebral cortex,testis: 0.4 ZG16B HRPE773, JCLN2, PRO1567 ENSG00000162078 Zymogen granule protein 16B 16 2830169-2839585 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041125, HPA053549 Supported Approved Nucleoplasm
Vesicles Endometrial cancer:3.48e-6 (favourable) Tissue enhanced Tissue enriched 210 salivary gland: 19669.3 prostate: 93.6 ADAM7 EAPI, GP-83 ENSG00000069206 ADAM metallopeptidase domain 7 8 24440930-24526970 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008879 Supported Group enriched Tissue enriched 198 epididymis: 4461.2 seminal vesicle: 22.5 KLK2 ENSG00000167751 Kallikrein-related peptidase 2 19 50861568-50880567 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000764 Supported Tissue enriched Tissue enriched 174 prostate: 850.1 testis: 4.8 SPZ1 FLJ25709, NYD-TSP1, PPP1R148 ENSG00000164299 Spermatogenic leucine zipper 1 5 80319625-80321842 Predicted intracellular proteins Evidence at protein level Group enriched Tissue enriched 170 testis: 45.0 epididymis: 0.2 ACPP ACP-3, ACP3, PAP ENSG00000014257 Acid phosphatase, prostate 3 132317367-132368298 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000071, HPA004335, HPA063916 Supported Tissue enriched Tissue enriched 153 prostate: 6368.2 esophagus: 41.6 MMP26 endometase, MGC126590, MGC126592 ENSG00000167346 Matrix metallopeptidase 26 11 4704927-4992429 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at transcript level Group enriched Tissue enriched 64 endometrium: 23.8 prostate,testis: 0.3 ACSM1 BUCS1, MACS1 ENSG00000166743 Acyl-CoA synthetase medium-chain family member 1 16 20623237-20698890 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046291 Uncertain Group enriched Tissue enriched 55 breast: 293.3 prostate: 5.2 RLN1 H1 ENSG00000107018 Relaxin 1 9 5334969-5339873 Plasma proteins, Predicted secreted proteins Evidence at transcript level Tissue enriched Tissue enriched 54 prostate: 33.4 testis: 0.6 CYP4F8 ENSG00000186526 Cytochrome P450, family 4, subfamily F, polypeptide 8 19 15615218-15630638 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058960 Approved Group enriched Tissue enriched 51 seminal vesicle: 145.8 prostate: 2.8 SEMG1 CT103, SEMG ENSG00000124233 Semenogelin I 20 45206997-45209772 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042476 Supported Tissue enriched Tissue enriched 41 seminal vesicle: 41038.6 prostate: 1007.2 PRAC1 C17orf92, PRAC ENSG00000159182 Prostate cancer susceptibility candidate 1 17 48721719-48722522 Predicted intracellular proteins Evidence at transcript level HPA047871 Approved Tissue enriched Group enriched 38 colon: 105.4;prostate: 197.0;rectum: 224.2 urinary bladder: 4.5 MYBPC1 ENSG00000196091 Myosin binding protein C, slow type 12 101568353-101686018 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA021004, HPA027614 Supported Breast cancer:4.76e-5 (favourable) Tissue enhanced Tissue enriched 37 skeletal muscle: 3919.3 prostate: 106.5 KLK4 EMSP, EMSP1, KLK-L1, PRSS17, PSTS ENSG00000167749 Kallikrein-related peptidase 4 19 50906352-50910738 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA051839 Supported Tissue enriched Tissue enriched 36 prostate: 395.8 skin: 10.9 POTEH A26C3, ACTBL1, CT104.7, POTE22 ENSG00000198062 POTE ankyrin domain family, member H 22 15690026-15721631 Predicted intracellular proteins Evidence at transcript level HPA042822 Uncertain Tissue enriched Group enriched 36 prostate: 5.7;testis: 1.3 all non-specific tissues: 0.0 MYL1 ENSG00000168530 Myosin, light chain 1, alkali; skeletal, fast 2 210290150-210315190 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA046859, HPA063034 Uncertain Head and neck cancer:6.59e-4 (unfavourable) Group enriched Tissue enriched 33 skeletal muscle: 7523.2 esophagus: 226.9 MSMB IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94 ENSG00000263639 Microseminoprotein, beta- 10 46033307-46046269 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB026357, HPA051257 Supported Urothelial cancer:7.19e-4 (favourable) Tissue enriched Tissue enriched 32 prostate: 18712.1 stomach: 590.2 MYL2 CMH10 ENSG00000111245 Myosin, light chain 2, regulatory, cardiac, slow 12 110910819-110920722 Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019763, HPA039262 Supported Uncertain Microtubules Head and neck cancer:2.60e-4 (unfavourable) Group enriched Group enriched 32 heart muscle: 13057.5;skeletal muscle: 9734.2 esophagus: 359.2 SEMG2 SGII ENSG00000124157 Semenogelin II 20 45221300-45224458 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042767, HPA042835 Supported Tissue enriched Tissue enriched 28 seminal vesicle: 13953.0 prostate: 501.7 TBX10 TBX13, TBX7 ENSG00000167800 T-box 10 11 67631303-67639560 Predicted secreted proteins, Transcription factors Evidence at protein level HPA047881 Uncertain Group enriched Group enriched 27 colon: 9.0;duodenum: 6.0;rectum: 8.8;small intestine: 10.8 appendix,testis: 0.3 MYH7 CMD1S, CMH1, MPD1 ENSG00000092054 Myosin, heavy chain 7, cardiac muscle, beta 14 23412738-23435718 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001239, HPA001349, CAB015384 Supported Group enriched Group enriched 26 heart muscle: 1925.5;skeletal muscle: 5112.2 esophagus: 136.3 SLC45A3 IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein ENSG00000158715 Solute carrier family 45, member 3 1 205657851-205680459 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA019073, HPA019075 Supported Approved Nucleoplasm
Vesicles Endometrial cancer:4.04e-5 (unfavourable), Urothelial cancer:7.33e-5 (favourable) Tissue enriched Tissue enriched 25 prostate: 430.6 stomach: 16.9 CEACAM20 UNQ9366 ENSG00000273777 Carcinoembryonic antigen-related cell adhesion molecule 20 19 44501677-44529788 Predicted membrane proteins Evidence at transcript level Group enriched Group enriched 24 duodenum: 39.9;prostate: 15.5;small intestine: 43.6 gallbladder: 1.3 BPIFB2 BPIL1, C20orf184, dJ726C3.2, LPLUNC2 ENSG00000078898 BPI fold containing family B, member 2 20 33007600-33023709 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA049491, HPA060121 Supported Approved Vesicles Endometrial cancer:1.97e-5 (favourable) Group enriched Group enriched 23 esophagus: 99.0;salivary gland: 91.0 cervix, uterine: 4.0 COX6A2 ENSG00000156885 Cytochrome c oxidase subunit VIa polypeptide 2 16 31427731-31428428 Predicted intracellular proteins, Transporters Evidence at protein level Group enriched Group enriched 23 heart muscle: 681.3;skeletal muscle: 1847.0 esophagus: 55.1 KLHL41 KBTBD10, Krp1, SARCOSIN ENSG00000239474 Kelch-like family member 41 2 169509702-169526262 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021165, HPA021753, HPA021760 Supported Supported Nucleus
Plasma membrane
Cytosol Group enriched Tissue enriched 22 skeletal muscle: 1750.9 esophagus: 80.0 TNNI1 ENSG00000159173 Troponin I type 1 (skeletal, slow) 1 201403768-201429866 Predicted intracellular proteins Evidence at protein level HPA028190 Approved Uncertain Nucleus
Nucleoli Head and neck cancer:9.27e-4 (unfavourable) Group enriched Tissue enriched 21 skeletal muscle: 4421.8 esophagus: 207.3 CHRNA2 ENSG00000120903 Cholinergic receptor, nicotinic, alpha 2 (neuronal) 8 27459761-27479883 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enriched 20 prostate: 43.0 breast: 2.1 KRTAP13-2 KAP13-2 ENSG00000182816 Keratin associated protein 13-2 21 30348075-30425912 Plasma proteins, Predicted intracellular proteins Evidence at protein level Tissue enhanced Group enriched 20 colon: 1.9;rectum: 2.0 all non-specific tissues: 0.0 CDH10 ENSG00000040731 Cadherin 10, type 2 (T2-cadherin) 5 24487100-24644978 Predicted membrane proteins Evidence at protein level HPA010651 Approved Group enriched Group enriched 19 cerebral cortex: 32.7;prostate: 6.8 adrenal gland: 1.0 NRAP ENSG00000197893 Nebulin-related anchoring protein 10 113588716-113664127 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA037953, HPA037954 Approved Group enriched Group enriched 19 heart muscle: 198.7;skeletal muscle: 814.2 esophagus: 26.5 ACTA1 ACTA, NEM3 ENSG00000143632 Actin, alpha 1, skeletal muscle 1 229431245-229434098 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000045, HPA041264, HPA041271 Supported Group enriched Tissue enriched 18 skeletal muscle: 45988.0 heart muscle: 2575.1 LMOD2 ENSG00000170807 Leiomodin 2 (cardiac) 7 123655807-123664290 Predicted intracellular proteins Evidence at protein level HPA051039 Supported Group enriched Group enriched 18 heart muscle: 464.3;skeletal muscle: 316.8 esophagus: 22.0 MYF6 bHLHc4, MRF4 ENSG00000111046 Myogenic factor 6 (herculin) 12 80707498-80709474 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level Head and neck cancer:2.05e-4 (unfavourable) Group enriched Tissue enriched 18 skeletal muscle: 99.2 esophagus: 5.3 SOX14 SOX28 ENSG00000168875 SRY (sex determining region Y)-box 14 3 137764284-137766338 Predicted intracellular proteins, Transcription factors Evidence at protein level Tissue enhanced Group enriched 18 placenta: 2.4;prostate: 1.1 testis: 0.1 TCAP CMD1N, LGMD2G, T-cap, TELE, telethonin ENSG00000173991 Titin-cap 17 39664187-39666555 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB004591, HPA026477 Supported Urothelial cancer:4.55e-4 (favourable) Group enriched Group enriched 18 heart muscle: 1974.6;skeletal muscle: 4964.5 esophagus: 196.1 CA3 CAIII, Car3 ENSG00000164879 Carbonic anhydrase III 8 85373436-85449040 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004967, HPA021775, HPA026700 Supported Breast cancer:4.24e-6 (favourable) Group enriched Tissue enriched 16 skeletal muscle: 1839.1 prostate: 112.8 CD177 HNA2A, NB1, PRV1 ENSG00000204936 CD177 molecule 19 43353659-43363172 Predicted secreted proteins Evidence at protein level HPA041820, HPA046601 Supported Cervical cancer:3.66e-4 (favourable) Tissue enhanced Group enriched 16 bone marrow: 193.4;colon: 159.0;prostate: 110.8;rectum: 184.1 appendix: 10.0 CT62 ENSG00000225362 Cancer/testis antigen 62 15 71110244-71115494 Predicted intracellular proteins Evidence at transcript level HPA045306 Uncertain Group enriched Tissue enriched 16 testis: 49.8 breast: 3.2 NPY PYY4 ENSG00000122585 Neuropeptide Y 7 24284163-24291865 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA009978, CAB016733, CAB034368, HPA044572, HPA056798 Supported Supported Validated Golgi apparatus Endometrial cancer:5.78e-4 (unfavourable) Tissue enriched Group enriched 16 adrenal gland: 154.2;cerebral cortex: 212.3;prostate: 448.9 appendix: 16.6 TRIM36 HAPRIN, RBCC728, RNF98 ENSG00000152503 Tripartite motif containing 36 5 115124762-115180546 Predicted intracellular proteins Evidence at protein level HPA061321 Approved Nucleus
Cytosol Tissue enhanced Tissue enriched 16 testis: 312.6 cerebral cortex: 19.9 CKM CKMM ENSG00000104879 Creatine kinase, muscle 19 45306414-45322977 Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047859 Supported Group enriched Tissue enriched 15 skeletal muscle: 23804.3 heart muscle: 1618.7 SLIT1 MEGF4, SLIL1, Slit-1, slit1, SLIT3 ENSG00000187122 Slit guidance ligand 1 10 96998038-97185920 Predicted secreted proteins Evidence at protein level Group enriched Tissue enriched 14 cerebral cortex: 60.2 thyroid gland: 4.1 GLYATL1 FLJ34646, MGC15397 ENSG00000166840 Glycine-N-acyltransferase-like 1 11 58905398-59043527 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039501 Supported Uncertain Golgi apparatus
Cytosol Renal cancer:3.03e-5 (favourable), Liver cancer:3.69e-4 (favourable) Group enriched Group enriched 13 kidney: 144.3;liver: 295.8 prostate: 16.3 NEFH ENSG00000100285 Neurofilament, heavy polypeptide 22 29480230-29491390 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB007786, HPA061615 Supported Approved Nucleus
Nuclear bodies
Centrosome Breast cancer:2.33e-6 (favourable) Group enriched Tissue enriched 13 prostate: 484.2 cerebral cortex: 37.4 TDRD1 CT41.1 ENSG00000095627 Tudor domain containing 1 10 114179270-114232304 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA037729, HPA037730 Uncertain Tissue enhanced Tissue enriched 13 testis: 31.9 kidney: 2.3 MB PVALB ENSG00000198125 Myoglobin 22 35606764-35637951 Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000060, HPA003123 Supported Group enriched Group enriched 12 heart muscle: 6691.4;skeletal muscle: 12286.7 esophagus: 767.2 NKX3-1 BAPX2, NKX3.1, NKX3A ENSG00000167034 NK3 homeobox 1 8 23678693-23682927 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level Tissue enriched Tissue enriched 12 prostate: 517.0 testis: 44.8 RPS4Y2 RPS4Y2P ENSG00000280969 Ribosomal protein S4, Y-linked 2 Y 20756164-20781032 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA000857 Uncertain Tissue enriched Group enriched 12 prostate: 3.3;testis: 2.2 tonsil: 0.2 SERHL2 ENSG00000183569 Serine hydrolase-like 2 22 42553617-42574382 Plasma proteins, Predicted intracellular proteins Evidence at transcript level Group enriched Tissue enriched 12 breast: 546.8 epididymis: 46.2 ABCC11 MRP8 ENSG00000121270 ATP-binding cassette, sub-family C (CFTR/MRP), member 11 16 48166910-48247568 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031980, HPA031981, HPA031982, CAB032513 Uncertain Group enriched Tissue enriched 11 breast: 63.2 prostate: 5.5 ACTC1 ACTC, CMD1R ENSG00000159251 Actin, alpha, cardiac muscle 1 15 34788096-34796139 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003761, CAB037330, HPA041264, HPA041271 Supported Approved Actin filaments Head and neck cancer:3.72e-5 (unfavourable), Urothelial cancer:9.32e-4 (unfavourable) Group enriched Tissue enriched 11 heart muscle: 2123.3 seminal vesicle: 189.9 B3GAT1 CD57, GlcAT-P, HNK-1, LEU7, NK-1 ENSG00000109956 Beta-1,3-glucuronyltransferase 1 11 134378504-134411918 Enzymes, Predicted intracellular proteins Evidence at protein level CAB002500, CAB010893, HPA069468 Supported Validated Vesicles Group enriched Tissue enriched 11 cerebral cortex: 115.7 thyroid gland: 10.3 CNTNAP2 Caspr2, KIAA0868, NRXN4 ENSG00000174469 Contactin associated protein-like 2 7 146116002-148420998 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002739 Supported Tissue enhanced Group enriched 11 cerebral cortex: 20.2;prostate: 5.7 breast,fallopian tube: 1.2 DEFB132 DEFB32, RP5-1103G7.6 ENSG00000186458 Defensin, beta 132 20 257736-261096 Predicted secreted proteins Evidence at protein level HPA046399 Supported Tissue enhanced Tissue enriched 11 epididymis: 326.7 seminal vesicle: 28.8 KCNC2 Kv3.2 ENSG00000166006 Potassium channel, voltage gated Shaw related subfamily C, member 2 12 75040077-75209868 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA019664, CAB022571 Uncertain Supported Plasma membrane
Cytosol Group enriched Tissue enriched 11 cerebral cortex: 46.5 prostate: 4.2 SLN MGC12301, MGC125854, MGC125855 ENSG00000170290 Sarcolipin 11 107707378-107719693 Predicted membrane proteins, Transporters Evidence at protein level CAB011628 Approved Microtubules Renal cancer:3.52e-9 (unfavourable) Group enriched Tissue enriched 11 skeletal muscle: 2802.5 heart muscle: 263.2 SRD5A2 ENSG00000277893 Steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) 2 31522480-31581067 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Group enriched Group enriched 11 epididymis: 27.4;fallopian tube: 31.2;liver: 30.6;prostate: 25.3;seminal vesicle: 24.2 testis: 2.4 STEAP2 IPCA-1, PCANAP1, STAMP1, STMP ENSG00000157214 STEAP family member 2, metalloreductase 7 90167590-90238137 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029115, HPA055603 Uncertain Supported Vesicles Tissue enriched Tissue enriched 11 prostate: 205.1 parathyroid gland: 18.5 SYNPO2L FLJ12921 ENSG00000166317 Synaptopodin 2-like 10 73644881-73663803 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA055192, HPA057142 Supported Approved Nuclear speckles
Cell Junctions
Cytosol Group enriched Group enriched 11 heart muscle: 158.4;skeletal muscle: 96.0 esophagus: 11.2 TMEM210 ENSG00000185863 Transmembrane protein 210 9 137170858-137172409 Predicted membrane proteins Evidence at protein level HPA066907 Supported Tissue enhanced Tissue enriched 11 testis: 10.5 salivary gland: 0.9 C22orf42 ENSG00000205856 Chromosome 22 open reading frame 42 22 32149006-32159322 Predicted intracellular proteins Evidence at transcript level HPA019531 Approved Group enriched Tissue enriched 10 testis: 10.7 prostate: 1.0 NCAPD3 CAP-D3, FLJ42888, hCAP-D3, hcp-6, hHCP-6, KIAA0056 ENSG00000151503 Non-SMC condensin II complex, subunit D3 11 134150119-134225454 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040286 Supported Nucleoplasm Tissue enriched Tissue enriched 10 prostate: 175.5 testis: 17.2 AK5 ENSG00000154027 Adenylate kinase 5 1 77282051-77559969 Enzymes, Predicted intracellular proteins Evidence at protein level HPA019128, HPA057255 Supported Supported Microtubule organizing center
Cytosol Prostate cancer:3.88e-4 (favourable) Group enriched Tissue enriched 9 cerebral cortex: 221.4 breast: 23.3 BHLHA15 bHLHa15, BHLHB8, MIST1 ENSG00000180535 Basic helix-loop-helix family, member a15 7 98211427-98212979 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB034083, HPA047834 Supported Approved Nucleoplasm
Golgi apparatus Tissue enhanced Group enriched 9 pancreas: 85.5;salivary gland: 54.2 prostate: 7.9 GNMT ENSG00000124713 Glycine N-methyltransferase 6 42960758-42963880 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA027501 Supported Approved Cytosol Liver cancer:1.86e-4 (favourable) Group enriched Group enriched 9 liver: 154.6;pancreas: 55.8;prostate: 34.2 breast: 9.3 RFPL2 RNF79 ENSG00000128253 Ret finger protein-like 2 22 32190435-32203477 Predicted intracellular proteins Evidence at transcript level HPA048320, HPA072380 Approved Nuclear speckles
Plasma membrane Prostate cancer:4.16e-4 (favourable) Tissue enriched Tissue enriched 9 prostate: 7.0 cerebral cortex: 0.8 MAPT DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau ENSG00000186868 Microtubule-associated protein tau 17 45894382-46028334 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000151, HPA048895, HPA069524, HPA069570 Supported Supported Nuclear speckles
Plasma membrane Group enriched Tissue enriched 8 cerebral cortex: 116.6 skeletal muscle: 13.7 RDH11 ARSDR1, MDT1, SDR7C1 ENSG00000072042 Retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 14 67676801-67695814 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB046011 Supported Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable) Tissue enriched Tissue enriched 8 prostate: 945.5 parathyroid gland: 123.3 TRPM8 ENSG00000144481 Transient receptor potential cation channel, subfamily M, member 8 2 233917398-234019522 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Liver cancer:7.15e-4 (favourable) Tissue enriched Tissue enriched 8 prostate: 128.7 liver: 16.3 CECR6 ENSG00000183307 Cat eye syndrome chromosome region, candidate 6 22 17116299-17121367 Predicted membrane proteins Evidence at protein level HPA068790 Approved Nucleoplasm
Vesicles
Plasma membrane Tissue enhanced Group enriched 7 cerebral cortex: 15.0;prostate: 10.9 testis: 1.9 NWD1 ENSG00000188039 NACHT and WD repeat domain containing 1 19 16719976-16817963 Predicted intracellular proteins Evidence at protein level Endometrial cancer:2.55e-4 (favourable) Tissue enriched Group enriched 7 cerebral cortex: 1.9;fallopian tube: 7.6;prostate: 5.8;seminal vesicle: 1.6 lung: 0.6 OPRK1 KOR, OPRK ENSG00000082556 Opioid receptor, kappa 1 8 53225716-53251697 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022595 Uncertain Tissue enhanced Group enriched 7 cerebral cortex: 3.6;prostate: 3.2;testis: 1.8 placenta,skeletal muscle: 0.3 OR51E2 PSGR ENSG00000167332 Olfactory receptor, family 51, subfamily E, member 2 11 4680171-4697854 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at transcript level Tissue enriched Tissue enriched 7 prostate: 38.9 placenta: 5.8 SPINK8 ENSG00000229453 Serine peptidase inhibitor, Kazal type 8 (putative) 3 48306842-48328341 Predicted secreted proteins Evidence at transcript level HPA053151 Uncertain Breast cancer:8.47e-4 (unfavourable) Group enriched Tissue enriched 7 breast: 57.1 bone marrow: 7.7 SPOCK3 testican-3 ENSG00000196104 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 4 166733384-167234796 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA075020 Approved Nucleus
Nucleoli
Golgi apparatus Tissue enhanced Tissue enriched 7 parathyroid gland: 791.1 prostate: 113.9 UPK3A UPK3 ENSG00000100373 Uroplakin 3A 22 45284982-45295874 Disease related genes, Predicted membrane proteins Evidence at protein level HPA018407, HPA018415 Supported Uncertain Nuclear membrane
Nuclear bodies Group enriched Group enriched 7 parathyroid gland: 12.8;prostate: 33.5;skeletal muscle: 12.6;urinary bladder: 16.0 thyroid gland: 2.6 ACER1 ASAH3 ENSG00000167769 Alkaline ceramidase 1 19 6306142-6333629 Enzymes, Predicted membrane proteins Evidence at transcript level Group enriched Tissue enriched 6 skin: 68.0 esophagus: 11.4 CHRM1 ENSG00000168539 Cholinergic receptor, muscarinic 1 11 62908679-62921807 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014101, CAB022366 Supported Approved Nucleus
Cytosol Tissue enriched Group enriched 6 cerebral cortex: 40.0;prostate: 40.1;salivary gland: 11.1 breast: 4.7 CRYM DFNA40 ENSG00000103316 Crystallin, mu 16 21238874-21303083 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA019086, HPA030619 Supported Supported Cytosol Tissue enhanced Group enriched 6 cerebral cortex: 102.6;heart muscle: 98.1;kidney: 56.5;prostate: 52.7;urinary bladder: 30.8 lung: 11.5 DNASE2B DLAD ENSG00000137976 Deoxyribonuclease II beta 1 84398532-84415018 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level Tissue enhanced Tissue enriched 6 salivary gland: 73.5 prostate: 11.3 FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase (prostate-specific membrane antigen) 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001451, HPA010593 Supported Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable) Tissue enriched Group enriched 6 duodenum: 307.0;prostate: 128.9;small intestine: 93.5 cerebral cortex: 31.1 LRRC26 bA350O14.10 ENSG00000184709 Leucine rich repeat containing 26 9 137168758-137170051 Predicted membrane proteins Evidence at protein level HPA056312 Approved Supported Plasma membrane Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable) Tissue enriched Group enriched 6 colon: 10.5;prostate: 29.3;salivary gland: 26.7 small intestine: 3.6 LUZP2 ENSG00000187398 Leucine zipper protein 2 11 24496970-25082631 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039007, HPA046161 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Group enriched Group enriched 6 adrenal gland: 8.5;cerebral cortex: 33.1 prostate: 3.3 PAGE4 CT16.7, GAGEC1, PAGE-4 ENSG00000101951 P antigen family, member 4 (prostate associated) X 49829260-49833973 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA023880 Supported Approved Golgi apparatus
Vesicles Group enriched Group enriched 6 epididymis: 1431.1;placenta: 2026.4 prostate: 279.7 SERPINB11 EPIPIN ENSG00000206072 Serpin peptidase inhibitor, clade B (ovalbumin), member 11 (gene/pseudogene) 18 63647579-63726432 Plasma proteins, Predicted intracellular proteins Evidence at transcript level Tissue enhanced Group enriched 6 esophagus: 28.8;prostate: 65.8 tonsil: 7.5 TTC6 C14orf25, NCRNA00291 ENSG00000139865 Tetratricopeptide repeat domain 6 14 37595847-38041442 Predicted intracellular proteins Evidence at protein level HPA069293 Uncertain Approved Centrosome Group enriched Group enriched 6 breast: 10.4;prostate: 26.3;testis: 10.4 stomach: 2.6 ACOXL FLJ11042 ENSG00000153093 Acyl-CoA oxidase-like 2 110732573-111118222 Predicted intracellular proteins Evidence at protein level HPA035392, HPA035393 Uncertain Supported Nucleoli
Cytosol Urothelial cancer:6.48e-4 (favourable) Group enriched Group enriched 5 epididymis: 9.2;lung: 14.6;parathyroid gland: 7.4;prostate: 5.5;testis: 5.3;urinary bladder: 8.0 thyroid gland: 1.6 C1QTNF9B CTRP9B ENSG00000205863 C1q and tumor necrosis factor related protein 9B 13 23891099-23902655 Predicted secreted proteins Evidence at protein level HPA056632 Uncertain Tissue enhanced Group enriched 5 prostate: 15.4;skin: 22.6;testis: 27.6 epididymis: 4.0 CCK ENSG00000187094 Cholecystokinin 3 42257825-42266207 Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002308, HPA045039 Supported Supported Group enriched Group enriched 5 cerebral cortex: 134.1;duodenum: 119.6;prostate: 32.8 small intestine: 18.1 FCN2 EBP-37, FCNL, ficolin-2, P35 ENSG00000160339 Ficolin (collagen/fibrinogen domain containing lectin) 2 9 134880812-134887520 Plasma proteins, Predicted secreted proteins Evidence at protein level Group enriched Tissue enriched 5 liver: 54.8 breast: 10.2 GRIN3A GluN3A ENSG00000198785 Glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 9 101569353-101738580 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 5 cerebral cortex: 12.4;cervix, uterine: 2.5 seminal vesicle: 1.4 KL ENSG00000133116 Klotho 13 33016433-33066145 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:1.29e-9 (favourable), Pancreatic cancer:4.44e-4 (favourable) Group enriched Group enriched 5 kidney: 135.6;parathyroid gland: 340.1 placenta: 43.7 PABPC1L2A RBM32A ENSG00000186288 Poly(A) binding protein, cytoplasmic 1-like 2A X 73077276-73079512 Predicted intracellular proteins Evidence at transcript level HPA041573 Approved Tissue enriched Group enriched 5 adrenal gland: 2.0;cerebral cortex: 6.7;prostate: 3.7;testis: 2.8 epididymis: 0.7 PABPC1L2B RBM32B ENSG00000184388 Poly(A) binding protein, cytoplasmic 1-like 2B X 73003517-73005713 Predicted intracellular proteins Evidence at transcript level HPA041573 Approved Tissue enriched Group enriched 5 cerebral cortex: 8.8;prostate: 4.5 testis: 1.2 PPFIA2 ENSG00000139220 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 2 12 81257975-81759553 Predicted intracellular proteins Evidence at protein level Tissue enhanced Tissue enriched 5 cerebral cortex: 61.2 testis: 11.4 PPM1E CaMKP-N, KIAA1072, POPX1, PP2CH ENSG00000175175 Protein phosphatase, Mg2+/Mn2+ dependent, 1E 17 58755869-58985176 Enzymes, Predicted intracellular proteins Evidence at protein level HPA018462, HPA019263 Approved Supported Nucleus
Nucleoli Tissue enhanced Group enriched 5 adrenal gland: 7.3;cerebral cortex: 20.5;testis: 12.1 fallopian tube: 2.4 SLC14A1 HsT1341, JK, RACH1, RACH2 ENSG00000141469 Solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 18 45724127-45752520 Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA058353, HPA059570 Supported Supported Vesicles Group enriched Group enriched 5 prostate: 132.1;urinary bladder: 51.9 cerebral cortex: 18.2 SLC23A1 SLC23A2, SVCT1, YSPL3 ENSG00000170482 Solute carrier family 23 (ascorbic acid transporter), member 1 5 139367196-139384553 Predicted membrane proteins, Transporters Evidence at protein level HPA047612 Supported Group enriched Group enriched 5 duodenum: 27.5;fallopian tube: 85.7;kidney: 41.7;small intestine: 73.4 liver: 10.7 SLC30A4 ZNT4 ENSG00000104154 Solute carrier family 30 (zinc transporter), member 4 15 45479611-45522807 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018178 Uncertain Pancreatic cancer:6.02e-4 (favourable) Tissue enriched Tissue enriched 5 prostate: 64.1 testis: 11.8 ABCC4 EST170205, MOAT-B, MOATB, MRP4 ENSG00000125257 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 13 95019829-95301446 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002476 Supported Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:2.25e-10 (favourable), Endometrial cancer:9.89e-4 (unfavourable) Tissue enriched Tissue enhanced prostate: 68.5 epididymis: 23.3 ACADL ACAD4, LCAD ENSG00000115361 Acyl-CoA dehydrogenase, long chain 2 210187939-210225491 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA011990 Supported Supported Renal cancer:1.58e-11 (favourable) Group enriched Tissue enhanced thyroid gland: 31.9 prostate: 25.1 ADRB1 ADRB1R ENSG00000043591 Adrenoceptor beta 1 10 114044056-114046908 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA067972 Supported Tissue enriched Tissue enhanced placenta: 45.2 heart muscle: 11.9 AGTR1 AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R ENSG00000144891 Angiotensin II receptor, type 1 3 148697784-148743008 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003596 Supported Uncertain Vesicles Group enriched Tissue enhanced placenta: 212.0 liver: 50.8 ALDH1A3 ALDH6, RALDH3 ENSG00000184254 Aldehyde dehydrogenase 1 family, member A3 15 100877714-100916626 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA046271, HPA064749 Approved Validated Nucleus
Cytosol Group enriched Tissue enhanced prostate: 209.6 adipose tissue: 74.0 ANKRD34B DP58 ENSG00000189127 Ankyrin repeat domain 34B 5 80556755-80570488 Predicted intracellular proteins Evidence at protein level HPA043327, HPA061740 Uncertain Approved Lipid droplets Tissue enhanced Tissue enhanced bone marrow: 1.1;lymph node: 1.0;tonsil: 1.2 kidney: 0.7 ANO7 IPCA-5, NGEP, PCANAP5, PCANAP5L, TMEM16G ENSG00000146205 Anoctamin 7 2 241188509-241225377 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035730 Uncertain Tissue enriched Tissue enhanced prostate: 86.9;stomach: 26.2 small intestine: 15.7 ARHGAP6 rhoGAPX-1 ENSG00000047648 Rho GTPase activating protein 6 X 11137543-11665701 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036779, HPA064390 Approved Renal cancer:1.55e-8 (favourable) Tissue enhanced Tissue enhanced prostate: 43.5;seminal vesicle: 42.8 thyroid gland: 42.2 ARHGEF38 FLJ20184 ENSG00000236699 Rho guanine nucleotide exchange factor (GEF) 38 4 105552620-105708093 Predicted intracellular proteins Evidence at protein level HPA036510, HPA045484 Approved Approved Nucleoplasm
Centrosome Tissue enhanced Tissue enhanced breast: 9.9 prostate: 8.4 ASB5 ENSG00000164122 Ankyrin repeat and SOCS box containing 5 4 176213673-176277571 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA028870 Uncertain Plasma membrane Head and neck cancer:5.67e-4 (unfavourable) Tissue enhanced Tissue enhanced skeletal muscle: 75.7 prostate: 18.1 AZGP1 ZA2G, ZAG ENSG00000160862 Alpha-2-glycoprotein 1, zinc-binding 7 99966720-99976157 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012582, CAB016087, CAB032276 Supported Renal cancer:1.53e-4 (favourable), Liver cancer:2.90e-4 (favourable) Group enriched Tissue enhanced breast: 1188.3;liver: 1270.8;prostate: 1556.6;salivary gland: 1431.4 kidney: 292.6 B3GNT6 B3Gn-T6 ENSG00000198488 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 11 77034398-77041973 Enzymes, Predicted secreted proteins Evidence at protein level HPA012158, HPA039805 Supported Approved Colorectal cancer:2.31e-4 (favourable) Group enriched Tissue enhanced colon: 22.1;rectum: 18.6;stomach: 24.0 small intestine: 8.0 BEND4 CCDC4, FLJ35632, FLJ43965 ENSG00000188848 BEN domain containing 4 4 42110938-42152878 Predicted intracellular proteins Evidence at protein level HPA036850 Uncertain Approved Nucleus
Nucleoli fibrillar center
Cytosol Group enriched Tissue enhanced prostate: 5.2;testis: 17.7 lymph node: 2.5 BMPR1B ALK6, CDw293 ENSG00000138696 Bone morphogenetic protein receptor, type IB 4 94757968-95158448 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009634 Uncertain Endometrial cancer:2.84e-4 (favourable) Tissue enhanced Tissue enhanced cervix, uterine: 37.0;prostate: 36.4 seminal vesicle: 20.8 BRINP3 DBCCR1L, DBCCR1L1, FAM5C ENSG00000162670 Bone morphogenetic protein/retinoic acid inducible neural-specific 3 1 190097662-190478404 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054693 Uncertain Group enriched Tissue enhanced cerebral cortex: 44.6;small intestine: 20.0 prostate: 10.5 C1orf64 ERRF, MGC24047 ENSG00000183888 Chromosome 1 open reading frame 64 1 16004236-16008807 Predicted intracellular proteins Evidence at transcript level HPA026676 Uncertain Approved Nucleoplasm Endometrial cancer:1.68e-6 (favourable) Tissue enhanced Tissue enhanced breast: 7.0 cervix, uterine: 3.7 CDH26 VR20 ENSG00000124215 Cadherin 26 20 59958427-60034011 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015722, HPA047578 Uncertain Approved Plasma membrane
Microtubules Lung cancer:3.75e-4 (favourable), Cervical cancer:7.62e-4 (favourable) Group enriched Tissue enhanced prostate: 19.8 urinary bladder: 6.3 CDH7 ENSG00000081138 Cadherin 7, type 2 18 65750252-65890341 Predicted membrane proteins Evidence at protein level HPA061419 Approved Tissue enhanced Tissue enhanced cerebral cortex: 2.8;prostate: 1.2 testis: 0.7 CFAP69 C7orf63, FAP69, FLJ21062 ENSG00000105792 Cilia and flagella associated protein 69 7 90245174-90311063 Predicted intracellular proteins Evidence at protein level HPA062883 Uncertain Tissue enhanced Tissue enhanced prostate: 24.6 fallopian tube: 17.4 CLDN8 ENSG00000156284 Claudin 8 21 30214006-30216073 Predicted membrane proteins, Transporters Evidence at protein level HPA060605 Approved Renal cancer:3.32e-4 (favourable) Tissue enhanced Tissue enhanced breast: 84.5;kidney: 75.5;rectum: 56.8 thyroid gland: 37.2 CLGN ENSG00000153132 Calmegin 4 140388455-140427968 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB020709, HPA048761, HPA058627 Supported Validated Endoplasmic reticulum Tissue enhanced Tissue enhanced testis: 185.4 heart muscle: 39.1 COL26A1 EMI6, EMID2, Emu2 ENSG00000160963 Collagen, type XXVI, alpha 1 7 101362820-101559024 Predicted secreted proteins Evidence at protein level HPA027059 Approved Approved Vesicles Liver cancer:2.32e-5 (favourable) Group enriched Tissue enhanced cerebral cortex: 10.2;parathyroid gland: 5.5 prostate: 2.9 CPNE4 COPN4, CPN4 ENSG00000196353 Copine IV 3 131533555-132285410 Predicted intracellular proteins Evidence at protein level HPA032036 Approved Nucleoplasm
Cytosol Tissue enriched Tissue enhanced cerebral cortex: 12.2;prostate: 41.7 seminal vesicle: 5.8 CREB3L4 AIbZIP, ATCE1, CREB3, CREB4, hJAL ENSG00000143578 CAMP responsive element binding protein 3-like 4 1 153967534-153974363 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA038122 Supported Approved Nucleoplasm
Nuclear membrane
Mitochondria Endometrial cancer:7.21e-4 (favourable) Group enriched Expressed in all prostate: 171.5 CRISP3 Aeg2, CRISP-3, CRS3, dJ442L6.3, SGP28 ENSG00000096006 Cysteine-rich secretory protein 3 6 49727384-49744437 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054392 Supported Group enriched Tissue enhanced fallopian tube: 1867.9;salivary gland: 923.6 esophagus: 289.4 CUX2 CDP2, CUTL2, KIAA0293 ENSG00000111249 Cut-like homeobox 2 12 111034024-111350554 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA044772 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 12.2;liver: 9.6;prostate: 17.1 thyroid gland: 6.8 CWH43 CWH43-C, FLJ21511 ENSG00000109182 Cell wall biogenesis 43 C-terminal homolog 4 48986247-49062081 Predicted membrane proteins Evidence at protein level HPA042814, HPA048140 Uncertain Renal cancer:2.29e-11 (favourable), Endometrial cancer:1.32e-4 (favourable) Tissue enhanced Tissue enhanced prostate: 69.1 skin: 29.7 CYP39A1 ENSG00000146233 Cytochrome P450, family 39, subfamily A, polypeptide 1 6 46549580-46652830 Enzymes, Predicted membrane proteins Evidence at protein level Renal cancer:1.86e-4 (favourable) Tissue enhanced Tissue enhanced liver: 56.7 epididymis: 28.4 DHRS7 retDSR4, SDR34C1 ENSG00000100612 Dehydrogenase/reductase (SDR family) member 7 14 60144120-60169856 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031121 Approved Approved Nucleoplasm
Mitochondria Renal cancer:1.92e-10 (favourable), Head and neck cancer:2.51e-4 (unfavourable), Breast cancer:6.42e-4 (favourable), Ovarian cancer:7.99e-4 (unfavourable) Tissue enriched Expressed in all prostate: 656.8 DLX1 ENSG00000144355 Distal-less homeobox 1 2 172084740-172089677 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA035666, HPA045884 Approved Approved Nucleus
Vesicles
Cell Junctions Tissue enhanced Tissue enhanced adrenal gland: 1.6;cerebral cortex: 5.0 prostate: 0.7 DNAH5 CILD3, Dnahc5, HL1, KTGNR, PCD ENSG00000039139 Dynein, axonemal, heavy chain 5 5 13690331-13944543 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA037469, HPA037470 Supported Tissue enhanced Tissue enhanced fallopian tube: 6.1;lung: 2.6 breast: 2.0 DNAH8 hdhc9 ENSG00000124721 Dynein, axonemal, heavy chain 8 6 38715341-39030529 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028447 Uncertain Tissue enriched Tissue enhanced testis: 14.2 prostate: 3.4 ELOVL2 Ssc2 ENSG00000197977 ELOVL fatty acid elongase 2 6 10980759-11044314 Enzymes, Predicted membrane proteins Evidence at protein level Breast cancer:6.73e-5 (favourable) Group enriched Tissue enhanced liver: 27.6;parathyroid gland: 39.5;placenta: 49.8 cerebral cortex: 22.9 FAM13C FAM13C1 ENSG00000148541 Family with sequence similarity 13, member C 10 59246129-59363181 Predicted intracellular proteins Evidence at protein level HPA037888 Approved Approved Nucleoplasm
Cytosol Tissue enhanced Mixed cerebral cortex: 39.5 FAM3B 2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44 ENSG00000183844 Family with sequence similarity 3, member B 21 41304212-41357431 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015885, HPA029777 Approved Approved Vesicles Tissue enhanced Tissue enhanced duodenum: 166.7;small intestine: 170.3 stomach: 124.7 FEV Pet-1 ENSG00000163497 FEV (ETS oncogene family) 2 218981087-218985657 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA067679 Supported Approved Nuclear speckles Pancreatic cancer:4.85e-4 (favourable) Group enriched Tissue enhanced adrenal gland: 2.1;duodenum: 3.0;stomach: 2.4 prostate: 1.9 FFAR2 FFA2R, GPR43 ENSG00000126262 Free fatty acid receptor 2 19 35443907-35451767 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA023985 Approved Tissue enhanced Tissue enhanced appendix: 26.2;bone marrow: 13.4 spleen: 11.1 FOXA1 HNF3A ENSG00000129514 Forkhead box A1 14 37589984-37596059 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB011595, HPA050505 Supported Supported Nucleoplasm
Nucleoli fibrillar center Urothelial cancer:1.00e-4 (favourable) Tissue enhanced Tissue enhanced prostate: 145.4 breast: 36.3 FOXB2 bA159H20.4 ENSG00000204612 Forkhead box B2 9 77019655-77020953 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA067947 Uncertain Tissue enhanced Not detected all non-specific tissues: 0.0 GABRG3 ENSG00000182256 Gamma-aminobutyric acid (GABA) A receptor, gamma 3 15 26971282-27541991 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054010 Supported Tissue enhanced Tissue enhanced prostate: 10.6;testis: 16.4 cerebral cortex: 4.2 GCSAML C1orf150, FLJ44728 ENSG00000169224 Germinal center-associated, signaling and motility-like 1 247507058-247577690 Predicted intracellular proteins Evidence at protein level HPA027507, HPA027510 Uncertain Approved Cytosol Tissue enriched Tissue enhanced prostate: 8.4;testis: 7.7 lung: 3.4 GJC3 CX30.2, GJE1 ENSG00000176402 Gap junction protein, gamma 3, 30.2kDa 7 99923269-99929620 Predicted membrane proteins, Transporters Evidence at protein level HPA015024 Uncertain Group enriched Tissue enhanced breast: 8.9;prostate: 5.6 testis: 3.2 GLB1L3 FLJ90231 ENSG00000166105 Galactosidase, beta 1-like 3 11 134274245-134319564 Predicted intracellular proteins Evidence at protein level HPA039916 Uncertain Lung cancer:1.97e-4 (favourable) Tissue enhanced Tissue enhanced prostate: 18.8;seminal vesicle: 10.7 cerebral cortex: 4.0 GLYATL1P3 ENSG00000255151 Glycine-N-acyltransferase-like 1 pseudogene 3 11 59086307-59094786 Predicted intracellular proteins Evidence at protein level HPA039501 Uncertain Uncertain Golgi apparatus
Cytosol Tissue enhanced Tissue enhanced breast: 10.9;lymph node: 3.5 tonsil: 2.1 GREB1 KIAA0575 ENSG00000196208 Growth regulation by estrogen in breast cancer 1 2 11482341-11642788 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024616, HPA027843, HPA028416 Uncertain Approved Mitochondria
Cytosol Endometrial cancer:1.05e-4 (favourable) Tissue enhanced Tissue enhanced ovary: 156.7 prostate: 54.3 GRIK1 GluK1, GLUR5 ENSG00000171189 Glutamate receptor, ionotropic, kainate 1 21 29536933-29940033 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA014623 Uncertain Glioma:9.12e-4 (unfavourable) Group enriched Tissue enhanced adrenal gland: 16.8;cerebral cortex: 9.1 prostate: 3.9 HOXA13 HOX1, HOX1J ENSG00000106031 Homeobox A13 7 27193503-27200106 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA046098 Approved Nucleoplasm
Intermediate filaments Tissue enhanced Tissue enhanced cervix, uterine: 33.9;placenta: 24.3;prostate: 36.5;seminal vesicle: 32.2 rectum: 13.3 HOXB13 ENSG00000159184 Homeobox B13 17 48724763-48729178 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004438, HPA062852, HPA065019 Supported Validated Nucleoplasm Tissue enriched Tissue enhanced prostate: 112.2;rectum: 39.9 colon: 21.9 HPSE2 HPA2, HPR2, UFS ENSG00000172987 Heparanase 2 (inactive) 10 98457077-99235862 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044603 Uncertain Tissue enhanced Tissue enhanced cervix, uterine: 53.9 esophagus: 22.8 IGSF21 MGC15730, RP11-121A23.1 ENSG00000117154 Immunoglobin superfamily, member 21 1 18107746-18378483 Predicted secreted proteins Evidence at protein level HPA044535 Approved Group enriched Tissue enhanced cerebral cortex: 29.0;spleen: 13.4 adrenal gland: 5.9 IL5RA CD125, CDw125, IL5R ENSG00000091181 Interleukin 5 receptor, alpha 3 3066326-3126613 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced fallopian tube: 22.5 lung: 4.9 KCNH6 erg2, HERG2, Kv11.2 ENSG00000173826 Potassium channel, voltage gated eag related subfamily H, member 6 17 63523334-63548977 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Tissue enhanced Tissue enhanced kidney: 6.1;prostate: 5.3;small intestine: 5.7 duodenum: 2.3 KCNN2 hSK2, KCa2.2 ENSG00000080709 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 2 5 114360945-114496500 Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA038221 Uncertain Uncertain Nucleoplasm
Cytosol Group enriched Tissue enhanced adrenal gland: 27.4;prostate: 18.5 liver: 15.9 KIAA1210 ENSG00000250423 KIAA1210 X 119078635-119150579 Predicted intracellular proteins Evidence at protein level HPA000551, HPA048322 Supported Tissue enhanced Tissue enhanced epididymis: 47.2;seminal vesicle: 27.1;testis: 58.1 prostate: 9.0 KIF5C ENSG00000168280 Kinesin family member 5C 2 148875250-149026759 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035210 Approved Approved Nucleoli
Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 205.9 prostate: 42.3 KLK15 ACO, HSRNASPH, prostinogen ENSG00000174562 Kallikrein-related peptidase 15 19 50825289-50837213 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA019802 Uncertain Tissue enhanced Tissue enhanced colon: 3.4;salivary gland: 2.4 adrenal gland: 1.8 LMAN1L ERGIC-53L, ERGL ENSG00000140506 Lectin, mannose-binding, 1 like 15 74812716-74825758 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Tissue enriched Tissue enhanced prostate: 81.3;spleen: 32.1 heart muscle: 15.7 MASP1 CRARF, MASP, PRSS5 ENSG00000127241 Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) 3 187217285-187292022 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001617, HPA009641 Supported Supported Nucleoplasm
Cytosol Liver cancer:2.20e-4 (favourable) Group enriched Tissue enhanced cervix, uterine: 155.2 endometrium: 97.4 MESP1 bHLHc5, MGC10676 ENSG00000166823 Mesoderm posterior bHLH transcription factor 1 15 89748661-89751310 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA069981 Supported Nucleus
Nucleoli Group enriched Tissue enhanced adipose tissue: 4.8;prostate: 4.0 cerebral cortex: 1.4 MYH11 SMHC, SMMHC ENSG00000133392 Myosin, heavy chain 11, smooth muscle 16 15703135-15857033 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002302, HPA014539, HPA015310 Supported Approved Plasma membrane
Cytosol Liver cancer:1.10e-5 (favourable) Tissue enhanced Tissue enhanced seminal vesicle: 1365.9;smooth muscle: 1008.5 prostate: 841.6 NKAIN1 FAM77C, FLJ12650 ENSG00000084628 Na+/K+ transporting ATPase interacting 1 1 31179745-31239554 Predicted membrane proteins Evidence at transcript level HPA006873 Uncertain Group enriched Tissue enhanced adrenal gland: 13.9;cerebral cortex: 13.1;skeletal muscle: 7.4 epididymis: 4.4 NPY4R PP1, PPYR1, Y4 ENSG00000204174 Neuropeptide Y receptor Y4 10 46461099-46465881 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA027863 Approved Tissue enhanced Tissue enhanced colon: 9.0;rectum: 10.5 skin: 6.4 NUDT10 DIPP3a, hDIPP3alpha ENSG00000122824 Nudix (nucleoside diphosphate linked moiety X)-type motif 10 X 51332231-51337525 Enzymes, Predicted intracellular proteins Evidence at protein level HPA047027, HPA057684 Approved Approved Cytosol Group enriched Tissue enhanced testis: 49.6 prostate: 24.3 OR51E1 GPR136, GPR164, OR51E1P, OR52A3P ENSG00000180785 Olfactory receptor, family 51, subfamily E, member 1 11 4643420-4655488 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level CAB019995, HPA051439 Approved Renal cancer:1.23e-6 (unfavourable) Tissue enriched Tissue enhanced adipose tissue: 6.3;placenta: 9.5;prostate: 8.0 urinary bladder: 1.8 PCDHGA5 CDH-GAMMA-A5, ME3, PCDH-GAMMA-A5 ENSG00000253485 Protocadherin gamma subfamily A, 5 5 141364232-141512979 Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Tissue enhanced Mixed cerebral cortex: 3.8 PDE11A ENSG00000128655 Phosphodiesterase 11A 2 177623252-178108339 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA034560 Uncertain Tissue enhanced Tissue enhanced epididymis: 14.2;parathyroid gland: 10.3 prostate: 8.5 PDLIM5 Enh, LIM ENSG00000163110 PDZ and LIM domain 5 4 94451857-94668227 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013511, HPA016740, HPA020026 Approved Supported Nucleoplasm
Plasma membrane
Focal adhesion sites Tissue enriched Expressed in all skeletal muscle: 407.0 PEBP4 CORK1, hPEBP4, MGC22776 ENSG00000134020 Phosphatidylethanolamine-binding protein 4 8 22713251-23000000 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA025064 Uncertain Group enriched Tissue enhanced epididymis: 462.3;lung: 173.6;skeletal muscle: 233.0 thyroid gland: 95.9 PGM5 PGMRP ENSG00000154330 Phosphoglucomutase 5 9 68328308-68531061 Predicted intracellular proteins Evidence at protein level CAB034397, HPA046329 Approved Renal cancer:1.83e-5 (favourable) Tissue enhanced Tissue enhanced prostate: 276.5;seminal vesicle: 324.8 smooth muscle: 215.4 PI15 P25TI ENSG00000137558 Peptidase inhibitor 15 8 74824537-74855029 Predicted secreted proteins Evidence at protein level HPA006593, HPA030057 Uncertain Group enriched Tissue enhanced appendix: 74.8;prostate: 45.0;smooth muscle: 66.9 endometrium: 32.7 PLA1A ps-PLA1 ENSG00000144837 Phospholipase A1 member A 3 119597842-119629811 Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA059740 Approved Nuclear speckles Cervical cancer:2.81e-7 (favourable) Group enriched Tissue enhanced epididymis: 162.2;seminal vesicle: 92.2 parathyroid gland: 38.1 PLA2G5 ENSG00000127472 Phospholipase A2, group V 1 20028179-20091190 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA053361 Approved Group enriched Tissue enhanced heart muscle: 50.0 seminal vesicle: 19.5 PNPLA7 C9orf111, FLJ31318, FLJ43070, FLJ44279, NTE-R1, NTEL1, RP11-48C7.2 ENSG00000130653 Patatin-like phospholipase domain containing 7 9 137459953-137550534 Predicted membrane proteins Evidence at protein level HPA009130 Uncertain Uncertain Microtubule organizing center
Cytosol Pancreatic cancer:2.24e-5 (favourable) Tissue enhanced Mixed prostate: 15.7 POTEG A26C2, CT104.4, POTE-14, POTE14, POTE14alpha ENSG00000187537 POTE ankyrin domain family, member G 14 19402486-19434341 Predicted intracellular proteins Evidence at transcript level HPA042822 Uncertain Tissue enhanced Tissue enhanced prostate: 3.3 testis: 0.7 PPP3CA CALN, CALNA, CNA1, PPP2B ENSG00000138814 Protein phosphatase 3, catalytic subunit, alpha isozyme 4 101023409-101348278 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA012778, CAB018581 Supported Validated Nucleoplasm
Cytosol Pancreatic cancer:3.82e-4 (unfavourable) Tissue enriched Expressed in all cerebral cortex: 164.8 PRAC2 C17orf93, HOXB-AS5, HOXB13-AS1, NCRNA00253 ENSG00000229637 Prostate cancer susceptibility candidate 2 17 48723168-48724758 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level Tissue enriched Tissue enhanced prostate: 19.0;rectum: 13.7 colon: 5.0 PRDM8 ENSG00000152784 PR domain containing 8 4 80183879-80204329 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA057253 Approved Nuclear bodies Tissue enhanced Tissue enhanced prostate: 41.3;seminal vesicle: 37.8 cerebral cortex: 23.3 PRR16 DSC54 ENSG00000184838 Proline rich 16 5 120464278-120687332 Predicted intracellular proteins Evidence at protein level HPA049254 Approved Approved Nucleus
Midbody
Cytosol Tissue enriched Mixed cervix, uterine: 21.6 RAB3B ENSG00000169213 RAB3B, member RAS oncogene family 1 51907956-51990764 Predicted intracellular proteins Evidence at protein level HPA003159, CAB023293 Supported Group enriched Tissue enhanced cerebral cortex: 8.2;prostate: 18.0 adrenal gland: 4.1 RAB6C WTH3 ENSG00000222014 RAB6C, member RAS oncogene family 2 129979664-129982738 Predicted intracellular proteins Evidence at protein level HPA059131 Uncertain Uncertain Golgi apparatus Tissue enhanced Tissue enhanced parathyroid gland: 15.1 cerebral cortex,prostate: 3.6 RANBP3L FLJ25422 ENSG00000164188 RAN binding protein 3-like 5 36248434-36302114 Predicted intracellular proteins Evidence at transcript level HPA037471, HPA037472, HPA061526 Approved Uncertain Nucleoplasm Tissue enhanced Tissue enhanced cerebral cortex: 31.1;kidney: 28.5;prostate: 21.7 breast: 10.0 RBFOX3 FOX-3, HRNBP3, NeuN ENSG00000167281 RNA binding protein, fox-1 homolog (C. elegans) 3 17 79089345-79516148 Predicted intracellular proteins Evidence at protein level HPA030790 Supported Supported Nucleoplasm Tissue enhanced Tissue enhanced cerebral cortex: 62.5;seminal vesicle: 33.0 prostate: 21.5 RIMS1 CORD7, KIAA0340, RAB3IP2, RIM, RIM1 ENSG00000079841 Regulating synaptic membrane exocytosis 1 6 71886703-72403143 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced cerebral cortex: 30.3 testis: 7.4 RLN2 bA12D24.1.1, bA12D24.1.2, H2, RLXH2 ENSG00000107014 Relaxin 2 9 5299868-5304969 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced fallopian tube: 8.0 parathyroid gland,prostate: 5.4 RORB NR1F2, ROR-BETA, RZRB ENSG00000198963 RAR-related orphan receptor B 9 74497365-74693177 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA008393 Uncertain Approved Nucleus Group enriched Tissue enhanced cerebral cortex: 12.6;cervix, uterine: 14.0 prostate: 7.6 RP11-1012A1.4 ENSG00000258466 14 67659820-67690367 Predicted intracellular proteins Evidence at transcript level Tissue enhanced Not detected appendix,gallbladder,urinary bladder: 0.5 RP11-520P18.5 ENSG00000261667 8 143080457-143083001 Predicted secreted proteins Evidence at transcript level Tissue enriched Tissue enhanced epididymis: 1.1 seminal vesicle: 0.7 SIM2 bHLHe15, MGC119447, SIM ENSG00000159263 Single-minded family bHLH transcription factor 2 21 36699133-36749917 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029295 Approved Supported Nucleoplasm
Nuclear bodies Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.88e-4 (favourable) Tissue enhanced Tissue enhanced esophagus: 22.9;kidney: 13.0 prostate: 9.1 SLC2A12 GLUT12, GLUT8 ENSG00000146411 Solute carrier family 2 (facilitated glucose transporter), member 12 6 133988697-134052636 Predicted membrane proteins, Transporters Evidence at protein level HPA031593, HPA031594 Approved Validated Plasma membrane
Cell Junctions Tissue enriched Tissue enhanced prostate: 38.8 endometrium: 15.7 SLC38A11 AVT2, FLJ39822 ENSG00000169507 Solute carrier family 38, member 11 2 164896186-164955525 Predicted membrane proteins, Transporters Evidence at transcript level HPA043432 Uncertain Renal cancer:2.00e-8 (favourable) Tissue enriched Tissue enhanced epididymis: 47.1;gallbladder: 28.3 seminal vesicle: 23.3 SLC44A4 C6orf29, CTL4, FLJ14491, NG22, TPPT ENSG00000204385 Solute carrier family 44, member 4 6 31863192-31879046 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046977, HPA054176 Approved Renal cancer:1.06e-6 (favourable), Head and neck cancer:3.54e-4 (favourable), Urothelial cancer:6.06e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 36.0 prostate: 30.1 SLC4A4 hhNMC, HNBC1, NBC1, NBC2, pNBC, SLC4A5 ENSG00000080493 Solute carrier family 4 (sodium bicarbonate cotransporter), member 4 4 71187286-71572087 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB022493, HPA035628, HPA035629 Supported Renal cancer:1.18e-4 (favourable), Colorectal cancer:7.69e-4 (favourable) Group enriched Tissue enhanced kidney: 124.6 cerebral cortex: 57.5 SMCO3 C12orf69, LOC440087 ENSG00000179256 Single-pass membrane protein with coiled-coil domains 3 12 14804650-14814182 Predicted membrane proteins Evidence at protein level HPA040574, HPA047804 Uncertain Tissue enhanced Tissue enhanced cervix, uterine: 5.6 gallbladder,kidney: 3.0 SPDEF bA375E1.3, PDEF ENSG00000124664 SAM pointed domain containing ETS transcription factor 6 34537802-34556333 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055707 Supported Nucleus
Nucleoli Endometrial cancer:9.26e-9 (favourable) Group enriched Tissue enhanced prostate: 154.8 breast,cervix, uterine: 42.1 SPOCK1 SPOCK, testican-1, TIC1 ENSG00000152377 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 5 136975298-137598379 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007450, HPA026770 Uncertain Approved Vesicles Head and neck cancer:1.93e-5 (unfavourable), Renal cancer:3.77e-5 (unfavourable), Colorectal cancer:1.93e-4 (unfavourable), Ovarian cancer:4.72e-4 (unfavourable), Lung cancer:9.08e-4 (unfavourable), Stomach cancer:9.40e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 209.7 prostate: 103.6 SPON2 DIL1 ENSG00000159674 Spondin 2, extracellular matrix protein 4 1166932-1208962 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA040170, HPA066095 Uncertain Approved Vesicles Endometrial cancer:2.03e-4 (favourable), Urothelial cancer:9.22e-4 (unfavourable) Tissue enriched Tissue enhanced endometrium: 105.3;prostate: 96.8 cervix, uterine: 53.6 STEAP1 PRSS24, STEAP ENSG00000164647 Six transmembrane epithelial antigen of the prostate 1 7 90154375-90164829 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA030985 Uncertain Tissue enriched Tissue enhanced prostate: 124.2 appendix: 41.5 STEAP4 FLJ23153, STAMP2, TIARP, TNFAIP9 ENSG00000127954 STEAP family member 4 7 88270892-88306891 Predicted membrane proteins, Transporters Evidence at protein level HPA075871 Supported Golgi apparatus Liver cancer:2.97e-4 (favourable), Stomach cancer:5.77e-4 (unfavourable) Tissue enhanced Expressed in all adipose tissue: 129.9 TBL1Y TBL1 ENSG00000092377 Transducin (beta)-like 1, Y-linked Y 6910686-7091683 Predicted intracellular proteins Evidence at protein level HPA060073 Uncertain Tissue enriched Tissue enhanced prostate: 2.5;thyroid gland: 1.4 testis: 0.5 TDRD6 bA446F17.4, CT41.2, NY-CO-45, SPATA36 ENSG00000180113 Tudor domain containing 6 6 46687875-46704319 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level Tissue enhanced Tissue enhanced testis: 42.6;thyroid gland: 20.3 spleen: 7.2 TENM1 ODZ1, ODZ3, TEN-M1, TNM ENSG00000009694 Teneurin transmembrane protein 1 X 124375903-124963817 Predicted membrane proteins Evidence at protein level HPA002848 Uncertain Group enriched Mixed cerebral cortex: 3.8 TMEFF2 CT120.2, HPP1, TENB2, TPEF, TR ENSG00000144339 Transmembrane protein with EGF-like and two follistatin-like domains 2 2 191949043-192195709 Predicted membrane proteins Evidence at protein level HPA015587 Uncertain Approved Microtubules
Cytokinetic bridge Tissue enriched Tissue enhanced cerebral cortex: 41.1;prostate: 54.9;seminal vesicle: 19.4 epididymis: 10.5 TMEM178A MGC33926, TMEM178 ENSG00000152154 Transmembrane protein 178A 2 39664982-39717963 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level HPA052128, HPA058560 Uncertain Approved Nucleus
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 55.6 kidney: 19.1 TMPRSS2 PRSS10 ENSG00000184012 Transmembrane protease, serine 2 21 41464551-41531116 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034493, HPA035787 Supported Supported Nucleoplasm
Cell Junctions Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable) Tissue enriched Tissue enhanced prostate: 495.7 stomach: 142.5 TMSB15A TMSL8, TMSNB ENSG00000158164 Thymosin beta 15a X 102513676-102516784 Predicted intracellular proteins Evidence at protein level Tissue enhanced Tissue enhanced prostate: 26.7 thyroid gland: 8.5 TRPV6 CaT1, ECAC2 ENSG00000165125 Transient receptor potential cation channel, subfamily V, member 6 7 142871203-142885762 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA062864 Approved Tissue enriched Tissue enhanced prostate: 38.7;salivary gland: 29.3 placenta: 17.4 UNC5D KIAA1777, Unc5h4 ENSG00000156687 Unc-5 netrin receptor D 8 35235457-35796550 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042940 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 9.2;duodenum: 6.2;prostate: 9.0 cervix, uterine: 3.4 USP9Y DFFRY ENSG00000114374 Ubiquitin specific peptidase 9, Y-linked Y 12701231-12860839 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA057687 Uncertain Vesicles Tissue enhanced Tissue enhanced prostate: 10.1 epididymis,seminal vesicle: 6.7 VGLL3 VGL-3 ENSG00000206538 Vestigial-like family member 3 3 86937969-86991119 Predicted intracellular proteins Evidence at protein level HPA054983 Approved Approved Nucleoli
Cytosol Tissue enhanced Tissue enhanced placenta: 57.4 adipose tissue: 24.2 VIPR1 HVR1, RDC1, VPAC1, VPAC1R ENSG00000114812 Vasoactive intestinal peptide receptor 1 3 42489299-42537573 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA026777 Approved Tissue enhanced Tissue enhanced lung: 60.0 duodenum: 35.4 VSTM2L C20orf102, dJ1118M15.2 ENSG00000132821 V-set and transmembrane domain containing 2 like 20 37903104-37945350 Predicted secreted proteins Evidence at protein level HPA043832 Uncertain Endometrial cancer:1.63e-5 (unfavourable), Urothelial cancer:8.14e-4 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 55.2 gallbladder: 26.9 ZBTB16 PLZF, ZNF145 ENSG00000109906 Zinc finger and BTB domain containing 16 11 114059593-114250676 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001499, CAB004540 Uncertain Renal cancer:2.21e-4 (favourable) Tissue enhanced Mixed ovary: 59.6 ZNF385B FLJ25270, ZNF533 ENSG00000144331 Zinc finger protein 385B 2 179441982-179861505 Predicted intracellular proteins Evidence at protein level HPA046086 Supported Nucleoli fibrillar center Renal cancer:1.04e-9 (favourable), Breast cancer:4.86e-8 (favourable) Group enriched Tissue enhanced lung: 27.4 prostate: 20.7